CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
CS-7017drug
Likely dose
CS-7017 0.05mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00408434
NCT00408434Phase 1Completed
CompareCT.gov

A Phase I Dose Finding Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Patients With Advanced or Malignancies

Daiichi Sankyo·interventional·Posted Dec 7, 2006·Updated Oct 19, 2020

In Brief

A Phase 1 clinical trial evaluating CS-7017 for Neoplasm. Completed, enrolled 32 participants across 2 sites.

Detailed Summary

An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 participants with advanced or metastatic malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 7, 2006
Enrollment StartNov 1, 2006
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.6 years ago

Interventions

CS-7017drug

CS-7017 0.05mg and 1.0mg tablets